Alnylam Pharmaceuticals
ALNY
#578
Rank
C$47.82 B
Marketcap
$369.49
Share price
-1.75%
Change (1 day)
80.35%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$5.50

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$5.79. In 2022 the company made an earnings per share (EPS) of -$13.09 a decrease over its 2021 EPS that were of -$10.15.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$5.50-58.01%
2022-$13.0929.03%
2021-$10.15-3.36%
2020-$10.50-8.48%
2019-$11.477.67%
2018-$10.6639.74%
2017-$7.6212.94%
2016-$6.7538.84%
2015-$4.86-32.88%
2014-$7.24259.44%
2013-$2.02-31.25%
2012-$2.9352.94%
2011-$1.9230.77%
2010-$1.47-8.77%
2009-$1.6178.13%
2008-$0.90-70.78%
2007-$3.0999.09%
2006-$1.55-43.88%
2005-$2.76-82.33%
2004-$15.64-59.23%
2003-$38.35

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.40-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$52.66-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$11.04 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.38-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.38-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.27-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.48-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$2.82-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel